The FDA’s Pharmacy Compounding Advisory Committee is convening July 23-24 to consider whether seven wellness peptides — BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax and epitalon — should be added to the agency’s Section 503A Bulk Drug Substances List.
The meeting arrives with FDA’s own staff already recommending against all seven, and with a panel roster that’s shifted twice in the run-up to the vote. Here’s what hospital leaders should know:
- BPC-157, KPV, TB-500 and MOTs-C are under review July 23, while emideltide (also called DSIP), Semax and epitalon follow July 24. Each substance is tied to a specific proposed use, not a blanket approval. For instance, BPC-157 is under review for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, and MOTs-C for obesity and osteoporosis. Emideltide is under review for opioid withdrawal, chronic insomnia and narcolepsy, Semax for cerebral ischemia, migraine and trigeminal neuralgia, and epitalon for insomnia.
- Under Section 503A, a compounded drug is exempt from FDA approval and manufacturing requirements only if the bulk substance complies with a USP monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List. None of the seven meet the first two conditions, which is why this week’s vote is the only legal opening available. All seven came off FDA’s restrictive Category 2 designation effective April 23, clearing the procedural path to the meeting.
- Ahead of the meeting, FDA’s own briefing documents already recommend against adding any of the seven peptides to the 503A Bulks List, and the docket has drawn roughly 1,860 public comments. The American Pharmacists Association is siding with FDA’s staff for now. In a July 9 comment letter to the committee, APhA said it supports FDA’s recommendation against adding any of the seven substances to the list at this time, barring new evidence presented during the comment period or at the meeting. The group’s reasoning centers on a few points. Without peer-reviewed clinical data, pharmacists lack the evidence to counsel patients on dosing, drug interactions or side effects. Adverse events tied to gray-market peptides are also difficult to trace back to the substance itself versus manufacturing contaminants, since sourcing is often unregulated. The letter also flags that large-scale compounded peptide production could fall outside Drug Supply Chain Security Act traceability requirements, which don’t typically apply to compounded preparations.
- The panel reviewing these peptides has drawn its own scrutiny. At the beginning of the month, the roster leaned toward physicians who run wellness, longevity and regenerative medicine clinics rather than the university researchers who staffed prior compounding panels, and at least one appointed member has separately promoted BPC-157 to his own social media following. However, the FDA has since added eight temporary voting members to the committee. The newest members include clinical researchers, professors of medicine, and pain and substance use experts. The additions came after criticism that the earlier roster was stacked with members tied to peptide-related businesses and clinics, although the FDA hasn’t said whether that criticism prompted the change.
- A “yes” this week is still a long way from a pharmacy shelf. PCAC’s recommendation is advisory, not binding. Even if the committee backs inclusion and the FDA agrees, formal notice-and-comment rulemaking would still be required — a process that typically runs well over a year, similar to the timeline still playing out on the 503B GLP-1 exclusions. A second PCAC meeting covering five more peptides, including GHK-Cu and Melanotan II, is expected before the end of February 2027.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.